Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 4/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HPSE | Q9Y251 | 3/20 | 0.37 |
| ▸ | PPARG | P37231 | 2/20 | 0.36 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CETP | P11597 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5834537 | 0.85 | HPSE (0.48) | RIPK1APEX1KMT2AMAPTMEN1 | |
| SCHEMBL5834480 | 0.82 | MAPT (0.42) | KMT2AMAPTMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL5835365 | 0.82 | RIPK1 (0.44) | RIPK1APEX1KMT2AMAPTMEN1 | |
| SCHEMBL5834739 | 0.80 | RIPK1 (0.41) | RIPK1KMT2AMAPTALDH1A1CCNT1 | |
| SCHEMBL5834594 | 0.80 | HPSE (0.57) | MAPTALDH1A1SMN1; SMN2HPSEPPARG | |
| SCHEMBL5834492 | 0.80 | APEX1 (0.51) | APEX1KMT2AMAPTMEN1ALDH1A1 | |
| SCHEMBL5835045 | 0.79 | MMP2 (0.53) | RIPK1KMT2AMAPTMEN1ALDH1A1 | |
| SCHEMBL6498374 | 0.79 | CETP (0.39) | RIPK1APEX1KMT2AMAPTMEN1 | |
| SCHEMBL5835003 | 0.79 | HPSE (0.59) | MAPTALDH1A1SMN1; SMN2HPSEPPARG | |
| SCHEMBL5834497 | 0.78 | MMP2 (0.58) | RIPK1KMT2AMAPTMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7138425-B2 | Phthalimide carboxylic acid derivatives | OXFORD GLYCOSCIENCE (UK) LTD. (GB) | 2006-11-21 | — | — | US | disclosed |
| US-20050203153-A1 | Phthalimide carboxylic acid derivatives | OXFORD GLYCOSCIENCE (UK) LTD. (GB) | 2005-09-15 | — | — | US | disclosed |
| EP-1483261-A1 | PHTHALIMIDE CARBOXYLIC ACID DERIVATIVES | Oxford GlycoSciences (UK) Ltd, Attn: Mary Gadsden (GB) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003074516-A1 | PHTHALIMIDE CARBOXYLIC ACID DERIVATIVES | OXFORD GLYCOSCIENCES (UK) LTD (GB) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203153-A1 | Phthalimide carboxylic acid derivatives | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, IDH1 | RIPK1 3380/4885APEX1 2470/4885KMT2A 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.